Evidence map›Paper›PMID 38383586›Full record

ArticleScientific reports2024

Quality of life and level of satisfaction with pharmacotherapeutic follow-up in a transgender health center in Brazil.

Carla Maria Lima Silva, Luiz Eduardo Oliveira Matos, Andressa Ribeiro Sassaqui, Alfredo Dias de Oliveira Filho, Chiara Erminia da Rocha, Giselle de Carvalho Brito

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Carla Maria Lima SilvaGraduate Program in Pharmaceutical Sciences, Federal University of Sergipe, São Cristóvão, Sergipe, Brazil.ORCID 0000-0002-1303-2103
Luiz Eduardo Oliveira MatosMultiprofessional Residency in Hospital Health Care, University Hospital of Lagarto, Lagarto, Sergipe, Brazil.ORCID 0000-0002-7470-273X
Andressa Ribeiro SassaquiGraduate Program in Applied Health Sciences, Federal University of Sergipe, Governador Marcelo Déda Avenue, São José District, Lagarto, Sergipe, 49400-000, Brazil.ORCID 0000-0002-0593-3497
Alfredo Dias de Oliveira FilhoGraduate Program in Pharmaceutical Sciences, Federal University of Sergipe, São Cristóvão, Sergipe, Brazil.ORCID 0000-0003-3192-8285
Chiara Erminia da RochaDepartment of Pharmacy, Federal University of Sergipe, Lagarto, Brazil.ORCID 0000-0002-1827-0856
Giselle de Carvalho BritoGraduate Program in Applied Health Sciences, Federal University of Sergipe, Governador Marcelo Déda Avenue, São José District, Lagarto, Sergipe, 49400-000, Brazil. gisellecbrito@academico.ufs.br.ORCID 0000-0002-3982-2138
Universidade Federal de Sergipe · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trans people face numerous barriers to access and permanence in health services, which makes it difficult, among other things, to know about their quality of life and satisfaction with health services related to these users. Thus, the objective was to describle the quality of life and satisfaction with pharmacotherapeutic follow-up in transgender people. A cross-sectional, descriptive, and quantitative study was conducted between January and September 2022 at a specialized outpatient clinic for transgender individuals. The following aspects were describle: sociodemographic and medication profiles; quality of Life, which was measured using the WHOQOL-BREF questionnaire; and levels of satisfaction with Pharmacotherapeutic Monitoring, assessed through the Pharmacy Services Satisfaction Questionnaire (QSSF). Descriptive analyses employed measures of central tendency, absolute and relative frequencies, while inferential analyses used the Student's t test. A total of 101 transgender individuals participated in the study, with a mean age of 25 years, the majority being single (79.2%/80), having more than 11 years of education (47.5%/n = 48), and comprising 48.5% (n = 49) transgender women. Hormone use was reported by 59.4% (n = 60) of the participants, with 18.3% (n = 11) of self-medication. Testosterone cypionate was the most common hormone used by transgender men (84%), while cyproterone acetate and estradiol represented 60.4% of hormone use among transgender women. Additionally, 36 transgender individuals were taking other drugs (n = 60), mainly antidepressives (28%). The WHOQOL-BREF showed higher scores in the domains of self-rated Quality of Life, and physical, and psychological well-being among transgender women compared to transgender men, but without statistical differences. Income revealed a statistically significant association with psychological domains and overall quality of life. The results of the QSSF indicated that the overall mean and average scores per question were higher than 4, suggesting that 100% of the sample was satisfied with the provided service. No statistically significant differences were observed in the Quality of Life between transgender men and women, but income was associated with the psychological domain and overall Quality of Life. All participants reported satisfaction with the Pharmacotherapeutic Monitoring service; however, there is a need to expand service offerings, such as medication dispensing.

Indexed as

Quality of LifeTransgender PersonsAdultBrazilCross-Sectional StudiesEstradiolFemaleFollow-Up StudiesHumansMalePersonal SatisfactionSurveys and QuestionnairesEstradiolHealth servicesPatient satisfactionQuality of lifeTransgender persons

Identifiers

PMID38383586
PMCPMC10881476
OpenAlexW4392002063

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.